CannabisNewsWire Announces Publication Discussing Biotech's Leading Role in the Cannabis Industry

New York, New York--(Newsfile Corp. - December 21, 2017) - CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for the cannabis industry, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of CNW and a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.

The publication, titled, "Biotech Market Banking on Big Cannabis Returns," discusses the innovation of today's biotech companies and the potential of the broader medicinal cannabis sector.

To view the full publication, visit:

InMed Pharmaceuticals, Inc.'s (CSE: IN) (OTCQB: IMLFF) market traction is based on the company's proprietary cannabinoid biosynthesis technology, one of three of its core assets and one which serves as the base for its development of its drug-development pipeline of novel therapeutics that leverage the pharmacological benefits of cannabinoids like CBD. As asked in a recent article, could InMed be the "next big thing in cannabis?" (

To date, most CBD research and drug development has focused on the most easily isolated CBDs, but multiple curative opportunities are believed to be found in the other 90+ cannabinoids of the marijuana plant. InMed is the only known company with the ability to isolate and bio-identically manufacture all of the naturally occurring CBDs found in the cannabis sativa plant (

Conducted in-house, InMed's cost-effective biosynthesis process enhances the production, purification and quality control compared to other chemical manufacturing methods, such as chemical synthesis. InMed's ability to produce its own pharmaceutical grade, bio-identical CBDs also sets it apart from other companies that rely on outside cultivators for their product supply.

About InMed

InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed's proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the company. For more information, visit

About CannabisNewsWire (CNW)

CannabisNewsWire ("CNW") is a specialized information service that (1) aggregates cannabis news, (2) provides CannabisNewsBreaks that quickly updates investors in the space, (3) enhances corporate press releases, (4) helps companies with distribution and optimization of social media, and (5) delivers comprehensive corporate communication solutions. CNW is uniquely positioned in the cannabis market with a strong team of journalists and writers who can help private and public companies reach a wide audience of investors, consumers, journalists and the general public through our ever-growing dissemination network of more than 5,000 key syndication outlets. CNW is bringing unparalleled visibility, recognition and content to the cannabis industry.

For more information please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

CNW Contact:

CannabisNewsWire (CNW)
Denver, Colorado
303.498.7722 Office